Irbesartan and Hydrochlorothiazide

Irbesartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension. Irbesartan and hydrochlorothiazide tablets may be used in patients whose blood pressure is not adequately controlled on monotherapy. Irbesartan and hydrochlorothiazide tablets may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of irbesartan and hydrochlorothiazide tablets as initial therapy for hypertension should be based on an assessment of potential benefits and risks.

12.1 Mechanism of Action Irbesartan Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth. Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT 1 angiotensin II receptor.

With Elimination kinetics span 5 to 11 hours per Irbesartan and Hydrochlorothiazide clinical pharmacology residence kinetics and Consistent 55%–67% gastrointestinal absorption profile for Irbesartan and Hydrochlorothiazide bioavailability, Irbesartan and Hydrochlorothiazide undergoes systemic clearance of irbesartan and hydrochlorothiazide integrates hepatic phase ii conjugation with renal filtration and establishes therapeutic activity over cmax attained 2–4 hours post-administration of irbesartan and hydrochlorothiazide.

Standard adult regimens span 150 mg/1 / 12.5 mg/1 Tablet, Film Coated, 150 mg/1 / 12.5 mg/1 Tablet, 300 mg/1 / 12.5 mg/1 Tablet, 300 mg/1 / 12.5 mg/1 Tablet, Film Coated, 300 mg/1 / 25 mg/1 Tablet, Film Coated. Prescribers screen specifically against irbesartan and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to any component of this product.; because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs., while community micro-logs most frequently note dizziness (8% of reports), fatigue (7.8% of reports), headache (6% of reports).